Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 1
1972 1
1975 1
1976 1
1978 2
1979 1
1980 1
1981 1
1982 1
1983 1
1984 3
1985 3
1986 1
1987 1
1988 2
1989 3
1990 2
1992 3
1993 1
1994 1
1995 2
1996 2
1997 2
1998 4
1999 1
2006 1
2007 1
2008 1
2009 4
2010 4
2011 4
2012 2
2013 4
2014 4
2015 10
2016 3
2017 3
2018 8
2019 4
2020 9
2021 4
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

102 results
Results by year
Filters applied: . Clear all
Page 1
CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.
Braun M, Aguilera AR, Sundarrajan A, Corvino D, Stannard K, Krumeich S, Das I, Lima LG, Meza Guzman LG, Li K, Li R, Salim N, Jorge MV, Ham S, Kelly G, Vari F, Lepletier A, Raghavendra A, Pearson S, Madore J, Jacquelin S, Effern M, Quine B, Koufariotis LT, Casey M, Nakamura K, Seo EY, Hölzel M, Geyer M, Kristiansen G, Taheri T, Ahern E, Hughes BGM, Wilmott JS, Long GV, Scolyer RA, Batstone MD, Landsberg J, Dietrich D, Pop OT, Flatz L, Dougall WC, Veillette A, Nicholson SE, Möller A, Johnston RJ, Martinet L, Smyth MJ, Bald T. Braun M, et al. Among authors: martinet l. Immunity. 2020 Oct 13;53(4):805-823.e15. doi: 10.1016/j.immuni.2020.09.010. Immunity. 2020. PMID: 33053330 Free article.
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.
Weulersse M, Asrir A, Pichler AC, Lemaitre L, Braun M, Carrié N, Joubert MV, Le Moine M, Do Souto L, Gaud G, Das I, Brauns E, Scarlata CM, Morandi E, Sundarrajan A, Cuisinier M, Buisson L, Maheo S, Kassem S, Agesta A, Pérès M, Verhoeyen E, Martinez A, Mazieres J, Dupré L, Gossye T, Pancaldi V, Guillerey C, Ayyoub M, Dejean AS, Saoudi A, Goriely S, Avet-Loiseau H, Bald T, Smyth MJ, Martinet L. Weulersse M, et al. Among authors: martinet l. Immunity. 2020 Oct 13;53(4):824-839.e10. doi: 10.1016/j.immuni.2020.09.006. Immunity. 2020. PMID: 33053331 Free article.
TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.
Guillerey C, Harjunpää H, Carrié N, Kassem S, Teo T, Miles K, Krumeich S, Weulersse M, Cuisinier M, Stannard K, Yu Y, Minnie SA, Hill GR, Dougall WC, Avet-Loiseau H, Teng MWL, Nakamura K, Martinet L, Smyth MJ. Guillerey C, et al. Among authors: martinet l. Blood. 2018 Oct 18;132(16):1689-1694. doi: 10.1182/blood-2018-01-825265. Epub 2018 Jul 9. Blood. 2018. PMID: 29986909 Free article.
Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment.
Nakamura K, Kassem S, Cleynen A, Chrétien ML, Guillerey C, Putz EM, Bald T, Förster I, Vuckovic S, Hill GR, Masters SL, Chesi M, Bergsagel PL, Avet-Loiseau H, Martinet L, Smyth MJ. Nakamura K, et al. Among authors: martinet l. Cancer Cell. 2018 Apr 9;33(4):634-648.e5. doi: 10.1016/j.ccell.2018.02.007. Cancer Cell. 2018. PMID: 29551594 Free article.
How tumors might withstand γδ T-cell attack.
Capietto AH, Martinet L, Fournié JJ. Capietto AH, et al. Among authors: martinet l. Cell Mol Life Sci. 2011 Jul;68(14):2433-42. doi: 10.1007/s00018-011-0705-7. Epub 2011 May 6. Cell Mol Life Sci. 2011. PMID: 21547501 Review.
Seizure onset location shapes dynamics of initiation.
Salami P, Peled N, Nadalin JK, Martinet LE, Kramer MA, Lee JW, Cash SS. Salami P, et al. Among authors: martinet le. Clin Neurophysiol. 2020 Aug;131(8):1782-1797. doi: 10.1016/j.clinph.2020.04.168. Epub 2020 May 29. Clin Neurophysiol. 2020. PMID: 32512346 Free PMC article.
102 results